Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Bossi

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Journal of Medical Virology|July 20, 2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsAnne-Geneviève Marcelin, Dissou Affolabi, Claire Lamotte, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Claire Lamotte, Constance Delaugerre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini, Patrizio Pezzotti, José M Miró, et al.
New Microbes and New Infections|June 1, 2023
Features of Mpox infection: The analysis of the data submitted to the ID-IRI networkGulden Eser-Karlidag, Enrique Chacon-Cruz, Yasemin Cag, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Journal of Medical Virology|July 20, 2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsAnne-Geneviève Marcelin, Dissou Affolabi, Claire Lamotte, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Claire Lamotte, Constance Delaugerre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini, Patrizio Pezzotti, José M Miró, et al.
New Microbes and New Infections|June 1, 2023
Features of Mpox infection: The analysis of the data submitted to the ID-IRI networkGulden Eser-Karlidag, Enrique Chacon-Cruz, Yasemin Cag, et al.
Pageof 7